ArticleInternational journal of molecular sciences2012
Boesenbergia pandurata attenuates diet-induced obesity by activating AMP-activated protein kinase and regulating lipid metabolism.
Article in International journal of molecular sciences, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 55 citations in OpenAlex.
- Panduratin A from Boesenbergia rotunda suppresses hepatitis B virus by targeting HNF1α and synergizing with antiviral agents.Chinese medicine · 2026Article
- Exploring the Anti-obesity Effects of Specific Medicinal Herbs: Focus on Herbal Approaches and their Role in Gut Microbiota.Current pharmaceutical biotechnology · 2025Review
- Efficient Simultaneous Isolation of Pinostrobin and Panduratin A fromMolecules (Basel, Switzerland) · 2024Article
- Oral sub-chronic toxicity of fingerroot (Toxicology reports · 2024Article
- Natural Chalcones for the Management of Obesity Disease.International journal of molecular sciences · 2023Review
- Inhibitory Effect of Isopanduratin A on Adipogenesis: A Study of Possible Mechanisms.Foods (Basel, Switzerland) · 2023Article
- Pinostrobin: An Adipogenic Suppressor from Fingerroot (Foods (Basel, Switzerland) · 2022Article
- Pharmacokinetics of panduratin A following oral administration of a Boesenbergia pandurata extract to rats.Journal of food and drug analysis · 2021Article
- Panduratin A Derivative Protects against Cisplatin-Induced Apoptosis of Renal Proximal Tubular Cells and Kidney Injury in Mice.Molecules (Basel, Switzerland) · 2021Article
- Vasorelaxant Effect ofPlants (Basel, Switzerland) · 2020Article
- Hypoglycemic effect of whole grain diet in C57BL/KsJ-Food science and biotechnology · 2019Article
- Article
- New Biflavonoids with α-Glucosidase and Pancreatic Lipase Inhibitory Activities from Boesenbergia rotunda.Molecules (Basel, Switzerland) · 2017Article
- Regulation of AMP-activated protein kinase by natural and synthetic activators.Acta pharmaceutica Sinica. B · 2016Review
- Transcriptome profiling shows gene regulation patterns in a flavonoid pathway in response to exogenous phenylalanine in Boesenbergia rotunda cell culture.BMC genomics · 2014Article
- AMP-activated protein kinase: maintaining energy homeostasis at the cellular and whole-body levels.Annual review of nutrition · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity, a chronic metabolic disorder, is characterized by enlarged fat mass and dysregulation of lipid metabolism. The medicinal plant, Boesenbergia pandurata (Roxb.) Schltr., has been reported to possess anti-oxidative and anti-inflammatory properties; however, its anti-obesity activity is unexplored. The present study was conducted to determine whether B. pandurata extract (BPE), prepared from its rhizome parts, attenuated high-fat diet (HFD)-induced obesity in C57BL/6J mice. The molecular mechanism was investigated in 3T3-L1 adipocytes and HepG2 human hepatoma cells. BPE treatment decreased triglyceride accumulation in both 3T3-L1 adipocytes and HepG2 hepatocytes by activating AMP-activated protein kinase (AMPK) signaling and regulating the expression of lipid metabolism-related proteins. In the animal model, oral administration of BPE (200 mg/kg/day for 8 weeks) significantly reduced HFD-induced body weight gain without altering the amount of food intake. In addition, elevated serum levels of total cholesterol, low-density lipoprotein cholesterol, and triglycerides were suppressed by BPE administration. Fat pad masses were reduced in BPE-treated mice, as evidenced by reduced adipocyte size. Furthermore, BPE protected against the development of nonalcoholic fatty liver by decreasing hepatic triglyceride accumulation. BPE also activated AMPK signaling and altered the expression of lipid metabolism-related proteins in white adipose tissue and liver. Taken together, these findings indicate that BPE attenuates HFD-induced obesity by activating AMPK and regulating lipid metabolism, suggesting a potent anti-obesity agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.